Skip to main content
ASCENTAGE PHARMA GROUP INTERNATIONAL logo

ASCENTAGE PHARMA GROUP INTERNATIONAL — Investor Relations & Filings

Ticker · AAPG ISIN · US04390B1052 US Manufacturing
Open in API
Filings indexed 102 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country US United States of America
Listing US AAPG

About ASCENTAGE PHARMA GROUP INTERNATIONAL

https://www.ascentage.cn/

Ascentage Pharma Group International is a global, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for cancers, chronic hepatitis B, and age-related diseases. The company aims to address unmet medical needs by creating first-in-class and best-in-class small-molecule drugs. Its core scientific expertise is in structure-based drug design and targeting key proteins that regulate apoptosis (programmed cell death). The company's pipeline features multiple drug candidates being evaluated in numerous clinical studies globally. Key assets include olverembatinib, a third-generation BCR-ABL inhibitor; lisaftoclax (APG-2575), a selective Bcl-2 inhibitor; and pelcitoclax (APG-1252), a dual Bcl-2/Bcl-xL inhibitor. These candidates have received multiple Fast Track, Orphan Drug, and Rare Pediatric Disease designations from global regulatory authorities.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 91% confidence The document is a Form 6-K ‘Report of Foreign Private Issuer’ filed with the SEC, referencing Exhibits consisting of press releases. It is a general regulatory submission (foreign issuer report) and does not itself present full financial statements, managerial commentary, or voting results. Therefore it falls under the catch-all Regulatory Filings category (RNS).
2026-06-01 English
CURRENT REPORT
Regulatory Filings Classification · 86% confidence The document is a Form 6-K “Current Report” filed by a foreign private issuer under the Securities Exchange Act, which simply furnishes a press release as Exhibit 99.1. It contains no substantive financial statements or management discussion, nor is it itself an AGM presentation, annual report, earnings release or other specific report type. As a miscellaneous SEC compliance filing, it falls into the Regulatory Filings (RNS) category.
2026-05-28 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 92% confidence The document is a Form 6-K, a current report by a foreign private issuer under the Securities Exchange Act of 1934. It furnishes a press release as Exhibit 99.1 regarding share purchases by a trustee for an RSU scheme. This is a regulatory filing rather than an annual or quarterly report, management discussion, or other specified category, so it falls under the catch-all “Regulatory Filings” category.
2026-05-28 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is an SEC Form 6-K 'Report of Foreign Private Issuer' under the Exchange Act, which is a periodic regulatory disclosure by a non-U.S. company (Ascentage Pharma). It does not contain full annual or quarterly financial statements, nor is it a press release or presentation. It is a regulatory filing outside the narrow categories (10-K, IR, ER, etc.), so it falls into the general “Regulatory Filings” fallback category (RNS).
2026-05-22 English
6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
Regulatory Filings
2026-05-13 English
6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
Regulatory Filings
2026-05-12 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.